Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

The pharmaceutical industry's lobbyists will really have to work for those millions once Congress comes back from its August recess.

Driving the news: Drug pricing will likely dominate the fall agenda in Congress.

  • The bipartisan leadership of the Senate Finance Committee — Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.) — released their long-awaited drug pricing bill yesterday. Finance is slated to mark it up on Thursday.
  • House Democrats, meanwhile, are planning to roll out their own bill after the recess — meaning both chambers could have their bills on the floor in September.

On the substance, the bipartisan Senate bill is pretty far-reaching, in the sense that it reaches into many parts of the system. The House bill may end up being more aggressive on its big-ticket items, though.

  • The Senate measure would cap price increases in Medicare Part D and Part B, put a cap on seniors' out-of-pocket costs, and reshape Part D more broadly to deal with some of the program's backwards incentives.

What they're saying: PhRMA, the industry's leading trade organization, said yesterday that the bill "fails to meet the fundamental test of providing meaningful relief at the pharmacy counter for the vast majority of seniors," while the White House signaled its support.

My thought bubble: Everyone's written a million stories about congressional Republicans being pulled between President Trump and some traditionally conservative idea or interest group.

  • But none of those traditional allies have brought as much campaign cash to the table as pharma. That tension could be real this time.
  • Even so, with a bipartisan framework to start and Trump's blessing on top of it, the industry will face a daunting challenge trying to stop the Senate from passing anything serious.
  • And if House Speaker Nancy Pelosi can get the progressives in her caucus on board, then we'd be back to the dynamic I mentioned yesterday: testing the bounds of Pelosi's and Trump's ability and willingness to make a deal.

Go deeper

1 hour ago - Health

Beware a Thanksgiving mirage

Illustration: Sarah Grillo/Axios

Don't be surprised if COVID metrics plunge over the next few days, only to spike next week.

Why it matters: The COVID Tracking Project warns of a "double-weekend pattern" on Thanksgiving — where the usual weekend backlog of data is tacked on to a holiday.

Trump pardons Michael Flynn

President Trump with Michael Flynn in 2016. Photo: David Hume Kennerly/Getty Images

President Trump on Wednesday pardoned his former national security adviser Michael Flynn, who pleaded guilty in the Mueller investigation to lying to FBI agents about his conversations with a former Russian ambassador.

Why it matters: It is the first of multiple pardons expected in the coming weeks, as Axios scooped Tuesday night.